Immune-related adverse events: what we've learned and where we're heading.
Authors: Badran YR, Leet DE, Dougan M PMID: 32726153 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 31, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Improving the accuracy of prognostication in chronic myelomonocytic leukemia.
Authors: Kaivers J, Schuler E, Hildebrandt B, Betz B, Rautenberg C, Haas R, Kobbe G, Gattermann N, Germing U Abstract INTRODUCTION: Chronic myelomonocytic leukemia (CMML) is a hematological malignancy that is extremely variable regarding its clinical course. It may present either as a chronic disorder with mild symptoms and low disease burden for several years, thereby justifying a watch-and-wait-strategy, or may soon progress to acute myeloid leukemia (AML) leaving allogeneic stem cell transplantation as the only curative treatment option. AREAS COVERED: Attempts have been made to integrate clinical, cytogenet...
Source: Expert Review of Anticancer Therapy - July 25, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma.
Authors: McClure E, Carr MJ, Zager JS Abstract INTRODUCTION: Mitogen-activated protein kinase (MAPK) signal transduction pathway inhibition through the use of agents binding to signal cascade kinases BRAF and MEK has become a key treatment strategy of patients with BRAF-mutant, unresectable melanoma. AREAS COVERED: Detailed analysis is undertaken of the current data, presenting the efficacy and safety of recently developed therapies targeting BRAF and MEK inhibition in the setting of unresectable melanoma. MAPK signal transduction, translational findings, current phase I, II and III clinical trials, and ongoing...
Source: Expert Review of Anticancer Therapy - July 17, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

The changing landscape of stage III lung cancer: a literature review.
This article reviews the treatment evolution of stage III NSCLC over the past decades, discusses current standard of care strategies and highlights potential future directions for the management of this condition. EXPERT OPINION: Ongoing trials incorporating upfront checkpoint inhibitors with radiotherapy will answer whether adding checkpoint inhibitors to chemotherapy or substituting them for chemotherapy altogether will improve long-term outcome. PMID: 32667262 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 17, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Authors: Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA Abstract INTRODUCTION: Waldenstrom's Macroglobulinemia (WM) is a rare, indolent lymphoplasmacytic lymphoma characterized by heterogeneous clinical and genomic profile. Bruton's tyrosine kinase (BTK) is central to the signaling pathways required for clonal WM cell survival, and BTK inhibitors currently have an imperative role in the treatment of WM. Areas covered: The central role of BTK in WM will be described, and the rationale behind the development of BTKi. Clinical trial data that led to the approval of ibrutinib (the first-in-class BTK...
Source: Expert Review of Anticancer Therapy - July 8, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies.
Authors: Sprenger T, Schirrmacher V, Stücker W, van Gool SW Abstract INTRODUCTION: Prospective double-blind placebo-controlled randomized clinical trials (RCTs) are considered standard for the proof of the efficacy of oncologic therapies. Molecular methods have provided new insights into tumor biology and led to the development of targeted therapies. Due to the increasing complexity of molecular tumor characteristics and of the individuality of specific anti-tumor immune reactivity, RCTs are unfortunately only of limited use. AREAS COVERED: The historical methods of drug research and approval and the relat...
Source: Expert Review of Anticancer Therapy - July 1, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Molecular therapeutic targets in non-small cell lung cancer.
We report data published regarding targeted therapies which are currently approved and for those which are emerging in advanced or metastatic NSCLC. EXPERT REVIEW: While these drugs have been shown to be efficacious and tolerable, resistance almost always develops. Though next-generation tyrosine kinase inhibitors (TKIs) have been developed, the appropriate sequencing of these drugs is not clear. Evaluating combination therapies to prevent or delay the onset of resistance and understanding mechanisms of resistance are critical areas of emerging research. PMID: 32580596 [PubMed - as supplied by publisher] (Source: E...
Source: Expert Review of Anticancer Therapy - June 27, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Radiotherapy in the era of COVID-19.
Authors: Lancia A, Bonzano E, Bottero M, Camici M, Catellani F, Ingrosso G PMID: 32552073 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - June 21, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
Authors: Manceau C, Mourey L, Pouessel D, Ploussard G Abstract INTRODUCTION: Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until invariable tumor regression. At the castration-resistant stage, metastatic disease becomes lethal. In recent years several new treatments, including second-generation hormone therapies, have proven to be life-prolonging in metastatic castra...
Source: Expert Review of Anticancer Therapy - June 21, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Identifying effective drug combinations for patients with acute myeloid leukemia.
Authors: Yilmaz M, Kadia T, Ravandi F Abstract INTRODUCTION: The development of high-throughput sequencing technologies and the relentless pursuit of quality translational and clinical research allowed us to understand the leukomogenesis driven by recurrent mutations and design targeted therapies. As a result, the landscape of standard acute myeloid leukemia (AML) therapy has remarkably changed; only within the last few years, eight new agents were approved by the Food and Drug Administration for patients with AML. AREAS COVERED: Although the addition of a new arsenal of AML drugs provides more options for pati...
Source: Expert Review of Anticancer Therapy - June 21, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

The emerging role of antibody-drug conjugates in urothelial carcinoma.
Authors: Lattanzi M, Rosenberg JE Abstract Introduction: In December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic urothelial carcinoma. Antibody-drug conjugates represent a new therapeutic modality in urothelial cancer; and beyond nectin-4, agents targeting Trop-2, HER2, and EpCAM are also in clinical development. Areas covered: This review outlines the biologic rationale and the clinical development o...
Source: Expert Review of Anticancer Therapy - June 21, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
Authors: Caparica R, De Angelis C, Fêde Â, Werutsky G, de Azambuja E Abstract INTRODUCTION: metronomic chemotherapy exerts its effects via inhibition of angiogenesis, immune modulation of the tumoral stroma, induction of senescence and apoptosis of tumor cells. Due to its favorable toxicity profile and its oral administration, metronomic chemotherapy arises as a promising alternative to be combined with endocrine therapy for the treatment of patients with luminal breast cancer. AREAS COVERED: the present manuscript reviews the rationale supporting the combination of metronomic chemotherapy and endoc...
Source: Expert Review of Anticancer Therapy - June 18, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

COVID-19: how will this impact children with cancer, now and in the future?
Authors: Kaspers GJL PMID: 32543935 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - June 18, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Palliative care for advanced gastric cancer.
Authors: Harada K, Zhao M, Shanbhag N, Baba H, Ajani JA Abstract INTRODUCTION: Proactive palliative care can effectively relieve symptoms early and effectively as well as improve quality of life of patients with gastric adenocarcinoma (GAC). AREAS COVERED: The review summarizes palliative care for GAC. GAC caused specific symptoms, such as malignant gastric outlet obstruction (GOO), bleeding, weight loss, and/or ascites, therefore these symptoms must be addressed specifically. EXPERT OPINION: Palliative care should start early to control general symptoms, thus may improve patient's condition to make the pat...
Source: Expert Review of Anticancer Therapy - June 18, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Neoadjuvant therapy for muscle-invasive bladder cancer.
Authors: Jain RK, Sonpavde G Abstract INTRODUCTION: Muscle-invasive bladder cancer (MIBC) is generally a highly aggressive malignancy with early and mostly distant recurrences. Cisplatin-based combinations have been established as neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) providing overall survival as well as disease-free survival benefit. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic urothelial carcinoma and are being tested in the neoadjuvant setting as well. AREAS COVERED: This review covers the existing guidelines for management of MIBC. It summari...
Source: Expert Review of Anticancer Therapy - June 18, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives.
Authors: Sartori G, Belluomini L, Lombardo F, Avancini A, Trestini I, Vita E, Tregnago D, Menis J, Bria E, Milella M, Pilotto S Abstract INTRODUCTION: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, acting as an irreversible and multitarget blocker of ErbB family members. Afatinib is currently approved for advanced non-small-cell lung cancer (NSCLC) harboring common and uncommon sensitizing EGFR mutations and for squamous NSCLC patients progressing after first-line platinum-based chemotherapy. AREAS COVERED: This review summarizes the efficacy and safety profil...
Source: Expert Review of Anticancer Therapy - June 14, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

The current clinical approach to newly diagnosed uterine cancer.
Authors: Filippova O, Leitao MM Abstract INTRODUCTION: Uterine cancer is the most common gynecologic malignancy, although fortunately, 75% of women present with early-stage disease. A major area of controversy regarding the management of the disease concerns postoperative therapy for both women with early- and advanced-stage endometrial carcinoma. Here, we review landmark evidence that can help guide clinical decision-making in the treatment of women diagnosed with endometrial cancer. AREAS COVERED: In this review, we present the latest data driving decisions for both surgical management and postoperative thera...
Source: Expert Review of Anticancer Therapy - June 14, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

PARP inhibitors in prostate cancer: time to narrow patient selection?
Authors: Antonarakis ES, Markowski MC PMID: 32521178 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - June 11, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Non-metastatic castration-resistant prostate cancer: current status and future directions.
Authors: Gupta R, Sheng IY, Barata PC, Garcia JA Abstract INTRODUCTION: The emergence of novel hormonal therapies and the increase availability of sensitive next-generation imaging techniques has significantly changed the management of recurrent prostate cancer. AREAS COVERED: In this review, we summarize the definition, diagnosis, treatment, and ongoing clinical trials in non-metastatic castration resistant prostate cancer (M0CRPC). We have also discussed the role of newer imaging modalities in the detection of advanced prostate cancer. EXPERT OPINION: M0CRPC is a disease state in prostate cancer...
Source: Expert Review of Anticancer Therapy - June 10, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
Authors: Donini M, Buti S, Massari F, Mollica V, Rizzo A, Montironi R, Bersanelli M, Santoni M Abstract INTRODUCTION: The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worsening in maximum 3-5 sites while all other tumor sites are controlled by systemic therapy. AREAS COVERED: We explore all possible approaches in these settings of patients: the role of local therap...
Source: Expert Review of Anticancer Therapy - June 3, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
Authors: Feld J, Belasen A, Navada SC Abstract INTRODUCTION: Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and allogeneic stem cell transplant. AREAS COVERED: This review provides an overview of the progress made over the past decade for emerging therapies for lower- and higher-risk MDS (MDS-HR). We also cover advances in prognostication, supportive care, and...
Source: Expert Review of Anticancer Therapy - June 3, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene.
Authors: Sun YQ, Li SQ, Zhao XS, Chang YJ Abstract INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curable strategy for acute lymphoblastic leukemia (ALL), especially for adult cases. However, leukemia relapse after allograft restricts the improvement of transplant outcomes. Measurable residual disease (MRD) has been the strongest predictor for relapse after allo-HSCT, allowing MRD-directed preemptive therapy. AREAS COVERED: This manuscript summarizes the detection of MRD in patients with ALL who undergo allo-HSCT, focusing the effects of positive pre-HSCT MRD and post-HSC...
Source: Expert Review of Anticancer Therapy - May 29, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Authors: Lee SS, McCue D, Pemmaraju N Abstract INTRODUCTION: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy that previously lacked standardized therapeutic approaches. CD123 (interleukin-3 receptor alpha unit) is highly expressed in many hematologic malignancies, including BPDCN. Tagraxofusp-ezrs (tagraxofusp from herein) is an agent that consists of interleukin-3 fused to a truncated diphtheria toxin, targeting CD123. The Food and Drug Administration recently approved tagraxofusp as therapy for BPDCN for adults and children aged 2 years and older. AREAS COVERE...
Source: Expert Review of Anticancer Therapy - May 29, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Authors: Qin Q, Patel V, Galsky MD Abstract INTRODUCTION: The recent approval of erdafitinib and the emergence of other potent and selective fibroblast growth factor receptor (FGFR) inhibitors (FGFRi's) are shifting the treatment paradigm for patients with advanced urothelial carcinoma (UC) harboring FGFR3 alterations. Whether such therapies can, and should, be combined with immune checkpoint inhibitors (ICI's) is an area of major research interest. Areas covered: Herein, we review the FGFR signaling pathway and impact of altered FGFR signaling on UC tumorigenesis, the clinical development of FGFRi's, the rationale...
Source: Expert Review of Anticancer Therapy - May 23, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan.
CONCLUSION: This analysis suggests that sorafenib has clinical benefit for mRCC patients regardless of baseline CVD. Serious ADRs increased for renal dysfunction. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT01411423. PMID: 32441582 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - May 23, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

The COVID-19 outbreak: a snapshot from down under.
Authors: van Zandwijk N, Rasko JEJ PMID: 32419533 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - May 19, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy.
Authors: Aragon-Ching JB, Dreicer R Abstract INTRODUCTION: The addition of the androgen-signaling inhibitors (ASI) apalutamide, enzalutamide and abiraterone acetate or docetaxel to standard androgen deprivation therapy (ADT) has been demonstrated to improve overall survival in men with hormone-sensitive metastatic prostate cancer (HSMPC).Areas covered: The majority of men presenting with metastatic prostate cancer will now benefit from the addition of either a novel ASI or docetaxel to standard ADT. In the absence of comparative studies of these agents, clinicians are left with assessing the individual studies and ...
Source: Expert Review of Anticancer Therapy - May 16, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

What is the best clinical approach to recurrent/refractory osteosarcoma?
Authors: Meazza C, Bastoni S, Scanagatta P Abstract Introduction: Osteosarcoma is the most common malignant bone tumor. It is currently treated with pre-and postoperative chemotherapy, associated with surgical resection of the tumor.Area covered: Relapses occur in about one in three patients presenting with localized disease, and three in four of those with metastases at diagnosis. Relapsing disease carries a very poor prognosis, with 5-year survival rates ranging between 13% and 40%.Expert opinion: Patients with unilateral lung involvement or solitary lung metastases and a recurrence-free interval (RFI) longer tha...
Source: Expert Review of Anticancer Therapy - May 9, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

How to face cancer treatment in the COVID-19 era.
Authors: Brandes AA, Di Nunno V PMID: 32370563 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - May 8, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Correction.
Authors: PMID: 32370564 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - May 8, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype.
This article summarizes the proceedings of the third edition of the Soft Tissue Sarcoma: Evidence and Experience symposium held March 2019 in Madrid, Spain. An update is provided of current approaches to advanced STS management. Case studies illustrate the role of trabectedin in advanced STS management.Expert opinion: First-line treatment of advanced STS requires distinct therapeutic strategies depending on goal: tumor shrinkage or tumor control. Since all sarcoma patients benefit from active treatment irrespective of age or line of therapy, oncologists have a duty to offer active systemic therapies unless the patient is u...
Source: Expert Review of Anticancer Therapy - May 2, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments.
Authors: Blay JY, Le Cesne A, Demetri GD Abstract Introduction: Soft tissue sarcomas (STS) encompass a group of rare and heterogeneous cancers. Rapid evolution in the field justifies a focused critical review of the clinical literature.Areas covered: Important advances, and associated controversies, in managing patients with STS are reviewed by treatment setting, histopathological subtype, and general management considerations. Despite many advances, opportunities remain to improve care to benefit patients. Areas of sarcoma research showing early promise indicate that new treatment development requires a deeper und...
Source: Expert Review of Anticancer Therapy - May 2, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
Authors: Spagnolo F, Croce E, Boutros A, Tanda E, Cecchi F, Mascherini M, Solari N, Cafiero F, Queirolo P Abstract Introduction: In recent years, the introduction of targeted therapy and immunotherapy into clinical practice has radically changed the management of advanced melanoma. More recently, these treatments also became the standard of care in the adjuvant setting. However, high-risk resectable stage III melanoma (i.e. with clinically detected regional lymph node involvement and/or satellites/in transit metastases) still has a high risk of relapse, even after adjuvant treatment, suggesting that the activity of...
Source: Expert Review of Anticancer Therapy - April 26, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

microRNAs as biomarkers of ovarian cancer.
Authors: Zhang H, Lu B Abstract Introduction: Ovarian carcinoma (OC) is the leading cause of death in women with gynecologic cancers. Most patients are diagnosed at an advanced stage with a low five-year survival rate of 20%-30%. Discovering novel biomarkers for early detection and outcome prediction of OC is an urgent medical need. miRNAs, a group of small non-coding RNAs, play critical roles in multiple biologic processes and cancer pathogenesis.Areas covered: We provide an in-depth look at the functions of miRNAs in OC, particularly focusing on their roles in chemoresistance and metastasis in OC. We also discuss...
Source: Expert Review of Anticancer Therapy - April 26, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Current radiotherapy techniques in NSCLC: challenges and potential solutions.
Authors: Giaj-Levra N, Borghetti P, Bruni A, Ciammella P, Cuccia F, Fozza A, Franceschini D, Scotti V, Vagge S, Alongi F Abstract Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered: In this review, we provide an overview of technological opportunities and future prospects in NSCLC management.Expert opinion: Stereotactic body radiotherapy (SBRT) is now...
Source: Expert Review of Anticancer Therapy - April 25, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Direct KRAS inhibition: progress, challenges and a glimpse into the future.
Authors: Grapsa D, Syrigos K PMID: 32320301 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 23, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Mogamulizumab in the treatment of advanced mycosis fungoides and S ├ęzary syndrome: safety and efficacy.
Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy. Expert Rev Anticancer Ther. 2020 Apr 22;: Authors: Lewis DJ, Rook AH Abstract Introduction: Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T-cell lymphoma characterized by a poor prognosis. Treatments are associated with high rates of relapse, and thus there exists an unmet medical need for new, improved therapies. Mogamulizumab is a novel defucosylated monoclonal antibody targeting C-C chemokine receptor 4 that eradicates malignant cells via antibody-dep...
Source: Expert Review of Anticancer Therapy - April 23, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development.
We describe the relationship to common genetic alterations found in glioma, and possible avenues to exploit these newly revealed mechanisms.Expert opinion: Improved understanding of the molecular underpinnings of this disease has been directly translated into treatment decisions and an improved ability to counsel patients regarding their prognosis. We are beginning to see the first glimmer of a return on the investment in regard to immunotherapy in malignant glioma, with further anticipated successful exploitations of the unique pathophysiology of glioma. PMID: 32301635 [PubMed - as supplied by publisher] (Source: Expe...
Source: Expert Review of Anticancer Therapy - April 19, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy.
Authors: Hulo P, Coupez D, Denis M, Bennouna J Abstract Introduction: Advanced non-small-cell lung cancers with EGFR mutation belong to the models of solid tumors which revealed the concept of oncogene addiction. For that reason, first, second and third generation EGFR tyrosine kinase inhibitors (TKIs) are the major anti-cancer drugs used in this indication. Translational research is currently focused on induced mechanisms of resistance and aims to define the best first therapeutic option and the best multiline strategy.Areas covered: EGFR TKIs, alone or in combination, i.e. anti-angiogenic drugs or chemotherapy, h...
Source: Expert Review of Anticancer Therapy - April 19, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
This article reviews the pharmacological properties, clinical efficacy, and safety of pexidartinib.Expert opinion: Pexidartinib was effective with an acceptable safety profile for advanced TGCT in phase I - III studies. The phase III trial (ENLIVEN) in unresectable TGCT met its primary endpoints of overall response - rate (ORR). These results led to FDA approval for this TGCT population. Mixed or cholestatic hepatotoxicity was observed in rare cases. For this reason, pexidartinib is currently available only through a Risk Evaluation and Mitigation Strategy (REMS) Program in the USA.TGCT significantly impairs patients' qual...
Source: Expert Review of Anticancer Therapy - April 18, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

How can biosimilars change the trajectory of breast cancer therapy?
Authors: Trapani D, Curigliano G PMID: 32298188 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 18, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Evolution in the management of soft tissue sarcoma: classification, surgery and use of radiotherapy.
Authors: Dei Tos AP, Bonvalot S, Haas R Abstract Background: Given the rapid evolution in the management of soft tissue sarcoma (STS), it is essential to revisit the evidence regularly. This review examines topics of interest for early management of STS: the impact of molecular genetics on sarcoma classification; the importance of a correct diagnosis and strategy in the surgical management of STS; current status on use of radiotherapy in STS.Areas covered: Accurate diagnosis of STS combines histomorphology, immunochemistry and molecular genetics, although morphology is the mainstay of therapeutic planning. As diagn...
Source: Expert Review of Anticancer Therapy - April 16, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy.
Authors: Leslie I, Boos LA, Larkin J, Pickering L Abstract Introduction: The incidence of advanced renal cell carcinoma (RCC) is increasing. Over the last ten years targeted therapies have led to improved efficacy outcomes for renal carcinoma, including longer survival. However, the majority of patients develop disease progression within a year of initiation of first-line therapy. Recently a number of new regimens have been investigated including the combination of immune checkpoint inhibitors with VEGF inhibitors.Areas covered: In this review we assess the efficacy and safety of avelumab/axitinib in treatment-na&i...
Source: Expert Review of Anticancer Therapy - April 16, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Foreword.
Authors: Blay JY PMID: 32266844 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 9, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Authors: Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S Abstract Introduction: Gene fusions are strong driver alterations in various cancers, increasingly diagnosed with multiple testing techniques. ROS1 fusions can be found in 1-2% of non-small cell lung cancer (NSCLC) and several tyrosine kinase inhibitors (TKIs) have been tested in this oncogene-driven disease. NTRK fusions are characteristic of a few rare types of cancer, also infrequently seen in some common cancers including NSCLC. Entrectinib is a newer ROS1 and NTRK inhibitor developed across different tumour types harbouring rearran...
Source: Expert Review of Anticancer Therapy - April 2, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Asbestos-related cancers: the 'Hidden Killer' remains a global threat.
Authors: van Zandwijk N, Reid G, Frank AL Abstract Introduction: Asbestos, the most frequent cause of occupational cancer, continues to be consumed on a massive scale, with millions of people exposed on a daily basis. This review explains why we have failed in curtailing the silent epidemic of asbestos-related disease and why the numbers of asbestos victims are likely to remain high. Emerging and developed countries have to be reminded that asbestos exposure has yet to become a problem of the past. The worldwide spread of asbestos, followed by the surge of asbestos-related cancers, resembles the lung cancer epidemi...
Source: Expert Review of Anticancer Therapy - April 2, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Addressing the controversial role of ketogenic diets in cancer treatment.
Authors: Klement RJ PMID: 32212835 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - March 29, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?
Authors: Goto T, Miyamoto H PMID: 32208041 [PubMed - as supplied by publisher] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - March 27, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Management of early stage gastro-oesophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.
Authors: Roy AC, Shapiro J, Burge M, Karapetis CS, Pavlakis N, Segelov E, Chau I, Lordick F, Chen LT, Barbour A, Tebbutt N, Price T Abstract Introduction: A multimodal approach in operable early stage oesophago-gastric (OG) cancer has evolved in the last decade, leading to improvement in overall outcomes.Areas covered: A review of the published literature and conference abstracts was undertaken on the topic of optimal adjunctive chemotherapy or chemoradiotherapy in early stage OG cancers. This review article focuses on the current evidence pertaining to neo-adjuvant and perioperative strategies in curable OG cancer...
Source: Expert Review of Anticancer Therapy - March 24, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Melanoma immunotherapy: strategies to overcome pharmacological resistance.
Authors: Trojaniello C, Vitale MG, Scarpato L, Esposito A, Ascierto PA Abstract Introduction: Although checkpoint inhibitors have provided a breakthrough in how melanoma is treated, about half of patients still do not respond due to primary or acquired resistance. New strategies are, therefore, required to increase the number of patients benefiting from immunotherapy. This systematic review investigates novel combinations that may overcome immune resistance in patients with melanoma.Areas covered: We provide an overview of immune-related resistance mechanisms and the various therapeutic strategies that can be consi...
Source: Expert Review of Anticancer Therapy - March 22, 2020 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research